We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ThalesNano Announces the Launch of New Products for its H-Cube
Product News

ThalesNano Announces the Launch of New Products for its H-Cube

ThalesNano Announces the Launch of New Products for its H-Cube
Product News

ThalesNano Announces the Launch of New Products for its H-Cube


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ThalesNano Announces the Launch of New Products for its H-Cube "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ThalesNano Inc. has validated and launched new products and applications for its H-Cube™ bench-top catalytic hydrogenator.

The new series of CatCarts™, ThalesNano's unique catalyst cartridge system for use in its flow reactors, filled with immobilized catalysts will enable scientists to carry out enantio-selective and stereo-selective catalytic hydrogenations while working with the H-Cube™.

These products will be launched at the American Chemical Society's 233rd National Meeting & Exposition, March 25-29, 2007, in Chicago, IL USA.,  Catalytic hydrogenation is one of the cleanest chemical transformations; however its safe handling has so far required expensive and special dedicated facilities.

ThalesNano's H-Cube™ hydrogenation bench top reactor can perform these transformations safely in standard laboratories even at high pressure and temperature. As a result of the extension of the application area, chemists will be able to perform otherwise complicated enantio-selective hydrogenation reactions in H-Cube™ routinely.

Laszlo Urge, CEO of International Operations said: "These new products will widen the application area of the H-Cube™ hydrogenation reactor significantly. Enantio-selective hydrogenation represents an important transformation in the search for novel biologically active compounds, and is a bottleneck in many of the pharmaceutical industrial processes. It also requires a special infrastructure that makes it less appealing for discovery chemistry.

The importance of enantio-selective hydrogenations is underlined by the fact that scientists who were pioneering this field were awarded the Nobel Prize in 2001 for their achievements.

An ever increasing number of chemists throughout the pharmaceutical and biotech industry are utilizing ThalesNano's revolutionary H-Cube™ that makes catalytic hydrogenation in laboratories significantly more effective than traditional methods.

It also allows easy automation even at high temperature and pressure. This enables chemists to carry out catalyst screening and quick process optimization while scanning a wide parameter range. As a result a large number of discovery protocols are currently created and they will be transferred to development and scale up for the production of clinical materials.

Due to the relatively easy scale up with ThalesNano flow reactors, the time required to transfer results from discovery to development could be shortened. Therefore we foresee great potential for entering process chemistry downstream from discovery with this new product family soon."

Dr. Ferenc Darvas, President and Chairman at ThalesNano commented "These products have great potential and will make the work of chemists more effective. We are finding more and more applications that cannot be solved with traditional methods.

It also underlines that ThalesNano is executing a strategy, where we could provide novel solutions not only for the discovery and for the development phases of the pharmaceutical industry, but for the petrochemical, food and cosmetics industry as well. These integrated solutions could effect both discovery and development and could help solve some of the bottlenecks in the R&D areas."

Advertisement